Thermo Fisher glioma companion test gets breakthrough designation

By staff writers

June 15, 2020 -- The U.S. Food and Drug Administration has granted breakthrough device designation to Thermo Fisher Scientific for its assay to identify two key mutations in patients with low-grade glioma.

The Oncomine Precision Assay can identify patients with low-grade glioma who have isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations. It runs on Thermo Fisher's Ion Torrent Genexus System, a comprehensive, automated next-generation sequencing platform that can deliver single-day genomic profiling results.

The assay is part of strategic partnership between Thermo Fisher and Agios Pharmaceuticals to develop a companion diagnostic for patients eligible for vorasidenib (AG-881), a dual IDH1/2 inhibitor in late-stage clinical development for the treatment of IDH-mutant low-grade glioma.

Thermo Fisher hopes to expand its Oncomine Precision Assay premarket approval to multiple cancer therapies, including liquid biopsy tumor profiling for lung cancer and solid tissue tumor profiling for multiple cancer types.

Q2 Solutions, Thermo Fisher partner on oncology testing
Thermo Fisher Scientific and clinical trial laboratory company Q2 Solutions are partnering on a plan to reduce the turnaround time for laboratory tests...
Thermo Fisher, WuXi, Mayo Clinic to develop COVID-19 test
Thermo Fisher Scientific announced it is working with WuXi Diagnostics and Mayo Clinic to develop a COVID-19 antibody test.
Thermo Fisher bee sting allergy test clears FDA
Thermo Fisher Scientific has received U.S. Food and Drug Administration clearance for its ImmunoCap Specific Immunoglobulin E Stinging Insect Allergen...
Thermo Fisher grows Q1 revenues
Revenues at Thermo Fisher Scientific grew 2% for the first quarter (end-March 31), although the company's net income slipped.
Thermo Fisher teams up with Ford on COVID-19 testing
Thermo Fisher Scientific and Ford Motor Co. are collaborating on the production of collection kits for COVID-19 tests.

Copyright © 2020

Last Updated ls 6/15/2020 1:51:12 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.